While the leading marker, CEA, has been used extensively to determine prognosis and to monitor disease progress and therapy after curative resection, it is not sufficiently specific based on its elevated level in other conditions, such as hepatitis, pancreatitis, inflammatory bowel disease and obstructive pulmonary disease, as well as pancreatic, gastric, lung and breast cancer. This evidence concerns the gene CEACAM5 and inflammatory bowel disease.